Search
Search Results
-
Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate
BackgroundAbiraterone acetate is an irreversible 17α-hydroxylase/C17, 20-lyase (CYP17) inhibitor approved for the treatment of metastatic...
-
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study
BackgroundWhile the cardiovascular risks of androgen receptor pathway inhibitors have been studied, they were seldom compared directly. This study...
-
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
BackgroundThere are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used...
-
Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate
PurposeWe assessed the impact of plasma trough concentrations of abiraterone (ABI) and its metabolite Δ4-abiraterone (D4A) and related polymorphisms...
-
Development of abiraterone acetate tablets with enhanced oral bioavailability
PurposeAbiraterone acetate (ABA), a precursor drug inhibiting androgen biosynthesis (CYP17 inhibitor), is used for treating metastatic...
-
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer
BackgroundWe aimed to develop and validate a plasma extracellular vesicle circular RNA (circRNA)-based signature that can predict overall survival...
-
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
BackgroundComorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic...
-
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer
Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment...
-
Pharmaceutical Product Characterization and Manufacturability of Surfactant-Enriched Oil Marbles with Abiraterone Acetate
The present study investigates the physicochemical properties and stability of a novel lipid-based formulation—surfactant-enriched oil marbles...
-
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
PurposeTo investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen...
-
Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling
Abiraterone acetate has very low bioavailability and drastic food effect to warrant a dosing regimen under fasting state only. Therefore, we aimed to...
-
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer
BackgroundAbiraterone (Abi) is an androgen receptor signaling inhibitor that significantly improves patients’ life expectancy in metastatic prostate...
-
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
BackgroundBlack men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with...
-
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
BackgroundDespite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to...
-
-
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
BackgroundEvidence suggests proton pump inhibitor (PPI) use may attenuate the effect of abiraterone acetate plus prednisone (AAP) in metastatic...
-
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
BackgroundAlthough the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains...
-
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
BackgroundMetastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the...
-
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
ObjectiveEvaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer...
